Logo image of TBMC

TRAILBLAZER MERGER CORP I (TBMC) Stock Fundamental Analysis

NASDAQ:TBMC - Nasdaq - US89278D1090 - Common Stock - Currency: USD

11.2  0 (0%)

Fundamental Rating

1

TBMC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. TBMC may be in some trouble as it scores bad on both profitability and health. TBMC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TBMC had positive earnings in the past year.
TBMC had a negative operating cash flow in the past year.
TBMC Yearly Net Income VS EBIT VS OCF VS FCFTBMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 500K -500K 1M

1.2 Ratios

Industry RankSector Rank
ROA 1.84%
ROE 6.75%
ROIC N/A
ROA(3y)0.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBMC Yearly ROA, ROE, ROICTBMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 0.5 -0.5 1 1.5

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TBMC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBMC Yearly Profit, Operating, Gross MarginsTBMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for TBMC has been increased compared to 1 year ago.
The debt/assets ratio for TBMC has been reduced compared to a year ago.
TBMC Yearly Shares OutstandingTBMC Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M
TBMC Yearly Total Debt VS Total AssetsTBMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.32, we must say that TBMC is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.09 indicates that TBMC is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACCN/A
TBMC Yearly LT Debt VS Equity VS FCFTBMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.93 indicates that TBMC may have some problems paying its short term obligations.
TBMC has a Quick Ratio of 0.93. This is a bad value and indicates that TBMC is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
TBMC Yearly Current Assets VS Current LiabilitesTBMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 200K 400K 600K 800K

More info and screens

1

3. Growth

3.1 Past

TBMC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.52%, which is quite impressive.
EPS 1Y (TTM)171.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TBMC Yearly Revenue VS EstimatesTBMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
TBMC Yearly EPS VS EstimatesTBMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 70.00, the valuation of TBMC can be described as expensive.
TBMC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.62.
Industry RankSector Rank
PE 70
Fwd PE N/A
TBMC Price Earnings VS Forward Price EarningsTBMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBMC Per share dataTBMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TBMC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAILBLAZER MERGER CORP I

NASDAQ:TBMC (2/20/2025, 8:00:00 PM)

11.2

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners59.26%
Inst Owner Change-90.86%
Ins Owners13.37%
Ins Owner ChangeN/A
Market Cap50.40M
AnalystsN/A
Price TargetN/A
Short Float %0.09%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 70
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)0.16
EY1.43%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS4.67
TBVpS4.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.84%
ROE 6.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)0.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z 0.32
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-269.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2457.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2457.65%
OCF growth 3YN/A
OCF growth 5YN/A